This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Pretargeting: A Path Forward for Radioimmunotherapy
- Myeloablative 131I-Tositumomab Radioimmunotherapy in Treating Non-Hodgkin's Lymphoma: Comparison of Dosimetry Based on Whole-Body Retention and Dose to Critical Organ Receiving the Highest Dose
- Patient-Specific Dosimetry of Pretargeted Radioimmunotherapy Using CC49 Fusion Protein in Patients with Gastrointestinal Malignancies
- Biodistribution of Yttrium-90-Labeled Anti-CD45 Antibody in a Nonhuman Primate Model
- Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma
- High-Dose 131I-Tositumomab (Anti-CD20) Radioimmunotherapy for Non-Hodgkin's Lymphoma: Adjusting Radiation Absorbed Dose to Actual Organ Volumes
- Potentiation of Radioimmunotherapy with Response-Selective Peptide Agonist of Human C5a
- PET Imaging of 86Y-Labeled Anti-Lewis Y Monoclonal Antibodies in a Nude Mouse Model: Comparison Between 86Y and 111In Radiolabels
- Radioimmunotherapy with 111In/90Y-2IT-BAD-m170 for Metastatic Prostate Cancer
- High-Dose Therapy with 90Yttrium-labeled Monoclonal Antibody CC49: A Phase I Trial
- Imaging and Phase I Study of 111In- and 90Y-labeled Anti-LewisY Monoclonal Antibody B3